请输入您要查询的百科知识:

 

词条 MMDA (drug)
释义

  1. Psychotherapeutic actions

  2. Pharmacology

  3. Legal Status

     United States  Australia 

  4. See also

  5. References

  6. External links

{{Drugbox
| drug_name = MMDA
| IUPAC_name = 1-(7-Methoxy-1,3-benzodioxol-5-yl)propan-2-amine
| image = MMDA-structure.png
| tradename =
| pregnancy_category =
| legal_CA = Schedule I
| legal_DE = Anlage I
| legal_UK = Class A
| legal_AU = Schedule 9
| legal_US = Schedule I
| routes_of_administration = Oral, Insufflation, Rectal
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number = 13674-05-0
| ATC_prefix = none
| ATC_suffix =
| PubChem = 26175
| ChemSpiderID = 24386
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RG7FY73ZAA
| C=11 | H=15 | N=1 | O=3
| molecular_weight = 209.24 g/mol
| smiles = O1c2cc(cc(OC)c2OC1)CC(N)C
}}

MMDA (3-methoxy-4,5-methylenedioxyamphetamine; 5-methoxy-MDA) is a psychedelic and entactogen drug of the amphetamine class. It is an analogue of lophophine, MDA, and MDMA.

MMDA was described by Alexander Shulgin in his book PiHKAL. Shulgin lists the dosage range of MMDA as 100–250 mg. The first effects appear within 30–60 minutes following oral administration. MMDA produces euphoria and loving warmth, and attenuates feelings such as anxiety and loneliness. MMDA also produces eyes-closed visuals, a state of drowsiness, muscle relaxation, and time distortion. Side effects include moderate mydriasis, dizziness, sensations of heat or cold, and trembling. The imagery is generally realistic, and often related to everyday perception of people, landscapes, or objects. The effects of MMDA usually reach a peak during the first hour following the initial effects, and begin to wane during the second hour, and usually completely disappear by the end of the fifth hour.

Psychotherapeutic actions

In his 1973 book, The Healing Journey, Claudio Naranjo explored the psychotherapeutic potential of MMDA. Like MDA, he found that MMDA facilitates communication and suggested it has potential applications in psychotherapy. Worldwide {{As of|2005|lc=on}}, MMDA has not been approved for any human applications.

Pharmacology

MMDA has been shown to act as a non-neurotoxic serotonin releasing agent with no effects on dopamine release and probably norepinephrine release as well,[1] and as a 5-HT2A receptor agonist.[2] The latter property is responsible for its psychedelic effects, whereas the former mediates its mood-lifting and empathogenic effects.

Legal Status

United States

MMDA is classified as a Schedule 1 substance in the United States, and is similarly controlled in other parts of the world. Internationally, MMDA is a Schedule I drug under the Convention on Psychotropic Substances.[3]

Australia

MMDA is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015).[4] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[4]

See also

  • 3,4-Methylenedioxyamphetamine (MDA)
  • Lophophine
  • Trimethoxyamphetamine (TMA)

References

1. ^{{cite journal |vauthors=McKenna DJ, Guan XM, Shulgin AT | title = 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine | journal = Pharmacology Biochemistry and Behavior | volume = 38 | issue = 3 | pages = 505–12 |date=March 1991 | pmid = 1829838 | doi = 10.1016/0091-3057(91)90005-M| url = http://linkinghub.elsevier.com/retrieve/pii/0091-3057(91)90005-M}}
2. ^{{cite journal |vauthors=Zhang Z, An L, Hu W, Xiang Y | title = 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach | journal = Journal of Computer-aided Molecular Design | volume = 21 | issue = 4 | pages = 145–53 |date=April 2007 | pmid = 17203365 | doi = 10.1007/s10822-006-9090-y }}
3. ^{{cite web|url=http://www.incb.org/pdf/e/list/green.pdf |title=Archived copy |accessdate=2005-11-19 |deadurl=yes |archiveurl=https://web.archive.org/web/20051205125434/http://www.incb.org/pdf/e/list/green.pdf |archivedate=2005-12-05 |df= }}
4. ^Poisons Standard October 2015 https://www.comlaw.gov.au/Details/F2015L01534
{{More citations needed|date=April 2010}}

External links

  • PiHKAL entry for MMDA
  • PiHKAL • info entry for MMDA
  • MMDA: A New Psychotomimetic Agent
  • Animal Pharmacology and Human Psychopharmacology of MMDA
  • A Pharmacological Comparison of MMDA and LSD In The Dog
{{Entactogens}}{{Monoamine releasing agents}}{{Serotonin receptor modulators}}{{Phenethylamines}}{{PiHKAL}}{{DEFAULTSORT:Methoxy-4,5-methylendioxyamphetamine, 3-}}

7 : Substituted amphetamines|Designer drugs|Entactogens and empathogens|Benzodioxoles|Phenol ethers|Serotonin receptor agonists|Serotonin releasing agents

随便看

 

开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。

 

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间:2024/11/10 23:36:17